Kennedy Capital Management LLC Has $6.15 Million Position in Immunome, Inc. $IMNM

Kennedy Capital Management LLC boosted its holdings in Immunome, Inc. (NASDAQ:IMNM) by 11.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 286,355 shares of the company’s stock after acquiring an additional 28,929 shares during the quarter. Kennedy Capital Management LLC’s holdings in Immunome were worth $6,151,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Assetmark Inc. acquired a new stake in Immunome in the 3rd quarter valued at $39,000. BNP Paribas Financial Markets boosted its holdings in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Strs Ohio purchased a new position in Immunome during the 4th quarter worth $64,000. Tower Research Capital LLC TRC boosted its holdings in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH purchased a new position in Immunome during the 3rd quarter worth $69,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 10,500 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $19.45 per share, for a total transaction of $204,225.00. Following the purchase, the director owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. The trade was a 31.90% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at $476,080. This represents a 30.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 139,438 shares of company stock valued at $2,964,664. 7.21% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IMNM has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Friday. Truist Financial lifted their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Leerink Partners cut their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Stephens cut their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Immunome Price Performance

NASDAQ IMNM opened at $18.07 on Tuesday. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -7.59 and a beta of 2.04. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The business’s fifty day moving average is $21.70 and its 200-day moving average is $21.71.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. Research analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.